| 08/11/21 | 07:00:09 | 8 Nov 2021 | | HUTCHMED to Present Clinical Data at ASH | RNS |
| 01/11/21 | 07:00:14 | 1 Nov 2021 | | HUTCHMED and AZ Initiate SAMETA Global P3 Trial | RNS |
| 29/10/21 | 09:30:02 | 29 Oct 2021 | | Total Voting Rights | RNS |
| 28/10/21 | 07:00:04 | 28 Oct 2021 | | HUTCHMED Initiates Phase III Trial of HMPL-523 | RNS |
| 20/10/21 | 09:30:03 | 20 Oct 2021 | | Grant of Awards under Long Term Incentive Plan | RNS |
| 30/09/21 | 09:30:07 | 30 Sept 2021 | | Total Voting Rights | RNS |
| 29/09/21 | 07:00:10 | 29 Sept 2021 | | Closure of Non-Core OTC Joint Venture Divestment | RNS |
| 29/09/21 | 07:00:10 | 29 Sept 2021 | | HUTCHMED Highlights Presentations at CSCO 2021 | RNS |
| 21/09/21 | 07:00:10 | 21 Sept 2021 | | HUTCHMED Initiates Phase III Trial SURTORI-01 | RNS |
| 20/09/21 | 07:00:09 | 20 Sept 2021 | | Japan Bridging Study For Surufatinib Initiated | RNS |
| 13/09/21 | 07:00:08 | 13 Sept 2021 | | Breakthrough Therapy Designation for Amdizalisib | RNS |
| 08/09/21 | 11:30:00 | 8 Sept 2021 | | HUTCHMED and AZ Initiate Phase III Trial in China | RNS |
| 07/09/21 | 09:30:08 | 7 Sept 2021 | | HUTCHMED to Present Clinical Data at ESMO | RNS |
| 06/09/21 | 07:00:08 | 6 Sept 2021 | | HUTCHMED Shares Included in Stock Connect Programs | RNS |
| 02/09/21 | 12:45:06 | 2 Sept 2021 | | Grant of Share Options, and Awards under LTIP | RNS |
| 31/08/21 | 09:30:01 | 31 Aug 2021 | | Total Voting Rights | RNS |
| 26/08/21 | 07:00:03 | 26 Aug 2021 | | Phase Ib/II Trial of Fruquintinib & Tislelizumab | RNS |
| 23/08/21 | 07:00:06 | 23 Aug 2021 | | HUTCHMED Selected for Certain Hang Seng Indexes | RNS |
| 17/08/21 | 09:30:03 | 17 Aug 2021 | | ELECTRONIC COMMUNICATION OF CORPORATE INFORMATION | RNS |
